Abacavir, dolutegravir, and lamivudine and Butisol Sodium
Determining the interaction of Abacavir, dolutegravir, and lamivudine and Butisol Sodium and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:Coadministration with inducers of UGT1A and CYP450 3A4 isoenzymes may decrease the plasma concentrations of dolutegravir, which is primarily metabolized by UGT1A1 with some contribution from CYP450 3A4. Dolutegravir is also a substrate of UGT1A3, UGT1A9, and P-glycoprotein in vitro. In 9 study subjects, administration of dolutegravir 50 mg once daily with rifabutin 300 mg once daily decreased dolutegravir trough plasma concentration (Cmin; 24 hours postdose) by 30% compared to administration without rifabutin. The clinical significance is unknown. Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution may be advisable if dolutegravir is used in combination with mild or moderate UGT1A/CYP450 3A4 inducers.
- "Product Information. Tivicay (dolutegravir)." ViiV Healthcare, Research Triangle Park, NC.
Generic Name: abacavir / dolutegravir / lamivudine
Brand name: Triumeq
Synonyms: Abacavir, Dolutegravir, and Lamivudine
Generic Name: butabarbital
Brand name: Butisol Sodium, Busodium
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Abacavir, dolutegravir, and lamivudine-Butorphanol
- Abacavir, dolutegravir, and lamivudine-Butorphanol injection
- Abacavir, dolutegravir, and lamivudine-Butorphanol Injection Solution
- Abacavir, dolutegravir, and lamivudine-Butorphanol nasal
- Abacavir, dolutegravir, and lamivudine-Butorphanol Nasal Solution
- Abacavir, dolutegravir, and lamivudine-Butorphanol Nasal Spray
- Butisol Sodium-Abacavir, Lamivudine and Zidovudine Tablets
- Butisol Sodium-Abacavir, lamivudine, and zidovudine
- Butisol Sodium-Abaloparatide
- Butisol Sodium-Abaloparatide Subcutaneous
- Butisol Sodium-Abatacept
- Butisol Sodium-Abatacept Auto-Injectors